Monograph Details
|
|
Immune System
> Immunization
|
|
IPOL |
| Manufacturer |
|
Sanofi Pasteur, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
IPV. |
| Generic Name |
|
Trivalent poliovirus vaccine; inactivated; whole virus grown in monkey kidney cells; IM or SC inj. |
| Indications |
|
Poliomyelitis immunization (virus Types 1, 2, and 3). |
| Children |
|
Inject IM or SC in midlateral thigh. Each dose is 0.5mL. Under 6 wks: not recommended. Full IPV schedule: One dose at 2 months, 4 months, 6–18 months, and 4–6 years of age. Sequential schedule with oral polio vaccine (OPV) (do not use OPV for immunocompromised patients or patients with immunocompromised household contacts): One dose of IPOL at 2 months and at 4 months of age, then 1 dose of OPV at 12–18 months and 1 dose of OPV at 4–6 years of age. |
| Adults |
|
Inject IM or SC in deltoid area. Each dose is 0.5mL. Previously unvaccinated: Two doses at a 1–2 month interval and a third dose 6–12 months later. Incompletely vaccinated: give 1–2 doses to complete series. Completely vaccinated: may give booster dose. |
| Contraindications |
|
Hypersensitivity to neomycin, streptomycin, or polymyxin B. May defer in acute febrile illness. |
| Precautions |
|
Have epinephrine inj (1:1000) available. Immunodeficiency. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Immunosuppressants: may get suboptimal response. |
| Adverse Reactions |
|
Local irritation, fever, sleepiness, fussiness, decreased appetite. |
| How Supplied |
Syringe 0.5mL (w. needle)—1, 10
Multidose vial (10 doses)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
